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Summary
BACKGROUND AND AIMS: In Switzerland, the preva-
lence of hepatitis C virus (HCV) among people who inject
drugs (PWID) has been decreasing owing to active harm
reduction efforts and an aging population. Recent ad-
vances in HCV therapeutics may provide an opportunity
to direct treatment to high-risk populations, with a goal of
reducing HCV prevalence and preventing new infections.
In order to guide these efforts, the current project was un-
dertaken with the following aims: (1) to develop a simple
model to estimate the number of new HCV infections us-
ing available data on PWID; (2) to examine the impact of
intervention strategies (prevention and treatment) on new
and total HCV infections among PWID.
METHODS: A dynamic HCV transmission model was
used to track HCV incidence and prevalence among active
PWID according to their harm reduction status. The rela-
tive impact of treating 1, 5, 10 or 15% of HCV+ PWID with
new oral direct acting antivirals was considered.
RESULTS: In 2015, there were an estimated 10 160 active
PWID in Switzerland, more than 85% of whom were en-
gaged in harm reduction programmes. Approximately 42%
of active PWID were HCV-RNA+, with 55 new viraemic in-
fections occurring annually. By 2030, a 60% reduction in
the HCV+ PWID population would be expected. In the ab-
sence of behavioural changes, the number of secondary
infections would increase under all treatment scenarios.
With high level treatment, the number of secondary in-
fections would peak and then drop, corresponding to de-
pletion of the viral pool. In Switzerland, 5% treatment of
the 2015 HCV+ PWID population per year would result in
a 95% reduction in total cases by 2030, whereas ≥10%
treatment would result in a >99% reduction.
CONCLUSIONS: Timely treatment of hepatitis C virus
among people who inject drugs is necessary to reduce the
prevalence and prevent new infections in Switzerland.
Key words: Switzerland, PWID, hepatitis C virus, HCV,
people who inject drugs, model, transmission, preva-
lence, incidence, treatment
Introduction
Modelling predicted that in 2013 there were nearly 83 000
viraemic hepatitis C virus (HCV) infections in Switzer-
land, a prevalence rate of approximately 1.0% [1]. Of
those, between 34 and 67% had a history of injection drug
use [2]. HCV-related complications are projected to in-
crease in Switzerland over the next 15 years unless mea-
sures are taken to reduce progression to advanced hepatic
fibrosis [1]. Focusing treatment on patients with advanced
HCV disease may be effective at preventing HCV-related
complications; however, it will do little to prevent new
infections. Treatment of HCV-infected people who inject
drugs (PWID) has been proposed as a method of prevent-
ing the spread of HCV and a key step in the elimination of
the disease; however, more information is needed to under-
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stand the impact that treatment within this population will
have on HCV incidence and prevalence.
In the wake of a disastrous escalation in illicit drug use
during the 1980s, Switzerland extended its strategic three-
pillar concept of prevention, treatment and law enforce-
ment to include a fourth pillar – harm reduction. This four-
fold policy has since become a success story. Its strategic
objectives include the decriminalisation of drug use, edu-
cation to encourage young people away from drugs, and
medical and social assistance for drug addicts. The main
components of the harm reduction measures are needle and
syringe exchange programmes (NSPs) and consumption
rooms run by major cities where users can inject or smoke
their drugs using sterile tools [3]. Although opioid substi-
tution treatment (OST) and heroin-assisted therapy (HAT)
are part of the treatment pillar, for the purposes of this
analysis they are considered to be a harm reduction mea-
sure because of their ability to reduce injection frequency
and prevent the transmission of HCV [4].
The percentage of injectors among PWID in Switzerland
has been decreasing as a result of these harm reduction ac-
tivities and the aging PWID population (average age 44
years) [5–7]. Provision of methadone substitution therapy
for opiate addicts has been covered by Swiss law since
1975, but also falls under the jurisdiction of local cantonal
statutes [8]. Methadone statistics are collected annually by
cantonal medical offices and provided to the Swiss Federal
Office of Public Health (FOPH), where an annual registry
is maintained [8]. HAT is available as a last-resort treat-
ment for adult long-term opioid users who have failed at
least two previous attempts at treatment [9]. HAT was first
introduced in Switzerland in 1994 and has been covered by
the Federal Law on Narcotics since 2008 [9, 10]. HAT par-
ticipation has been monitored by the Swiss Research Insti-
tute for Public Health since 2000, via the Swiss monitoring
system of HAT [9, 11].
Additionally, NSPs are available to all PWID in Switzer-
land, although uptake of services is difficult to estimate.
Alongside the provision of sterile needles and syringes,
NSPs provide sterile filters, water and cookers. This equip-
ment is provided through safe injecting rooms, low thresh-
old facilities, methadone clinics, general practitioners,
pharmacies and in some cities can be purchased through
vending machines. NSPs are also provided in some pris-
ons; however, this practice does not occur nationwide.
Understanding the impact of harm reduction efforts and
treatment on the HCV infected PWID population requires
robust epidemiological modelling. The goals of this project
were twofold: (1) to develop a simple model to estimate
the number of new HCV infections using available data on
PWID; (2) to examine the impact of intervention strategies
(prevention and treatment) on new and total HCV infec-
tions among PWID.
Methods
Defining the population of interest
In order to model the PWID population, standard defin-
itions were necessary. For the purposes of this analysis,
PWID referred to an individual who has injected illicit
drugs within the past 12 months. OST participant referred
to an individual receiving opiate substitution to manage
past or present opioid addiction. Subsets of OST partici-
pants continue to use illicit drugs (parallel consumption),
and among those who use illicit drugs, some do so by
means of injection. High coverage NSP is defined as one
or more sterile syringes received for every injection. This
was estimated using the number of syringes distributed and
the average number of injections per day.
Modelling the PWID population
The HCV transmission model was developed as an add-
on module to a previously described HCV disease burden
model [1, 12, 13]. Among PWID, the population was de-
fined by HCV infection (susceptible or infected) and risk-
behaviour status (sharing needles or not sharing). PWID
were modelled to move across segments in a limited num-
ber of directions. Behaviour changes resulting in needle
sharing (among those previously not sharing) or in a dis-
continuation of needle sharing (among those previously
sharing) could occur. Additionally, PWID who shared nee-
dles and were previously not infected with HCV could be-
come infected. And finally, PWID who were HCV infect-
ed (regardless of sharing behaviours) could be treated and
cured of their HCV.
PWID exited the model as a result of mortality (estimated
at an annual rate of 1.38%) [5] or cessation of injection
drug use. The rate of cessation was calculated on an annual
basis to match historical trends in the overall PWID pop-
ulation size. The number of new PWID was calculated to
balance the number of PWID leaving the population. Ad-
ditionally, participation in high-coverage NSPs, OST, and
NSPs plus OST was modelled. After 2015, all inputs were
modelled to remain constant.
Modelling new infections
New infections were calculated as the probability of infec-
tion multiplied by the size of the PWID population that
was sharing needles but not currently HCV infected. The
estimated probability of infection was calculated from the
average annual number of unsafe injections, HCV preva-
lence among shared syringes and the probability of HCV
transmission from a contaminated needle (1.8%, range
0.0–10.3%) [14–16]. Among PWID who did not share in-
jection equipment, the probability of getting infected was
dependent on the background HCV prevalence (1% among
adults in Switzerland) alone. Engagement in an NSP or
OST was assumed to result in a 59% reduction in unsafe
injections, and simultaneous involvement in an NSP and
OST was assumed to result in an 81% reduction in unsafe
injections [17–22]. Among HAT participants, a 75% reduc-
tion in unsafe injections was estimated since heroin was
dispensed and tied to stationary consumption with clean
syringes (expert consensus).
Estimating the size of the HCV-infected PWID popula-
tion
PWID population
There are 8000–12 000 active PWID in Switzerland, in-
cluding those who inject while engaged in OST and NSP
programmes (personal communication, Dr Jean-Pierre
Gervasoni of Centre Hospitalier Universitaire Vaudois, and
expert consensus). The number of PWID has been decreas-
ing over the last 20 years owing to harm reduction efforts
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and the aging PWID population (average age 44 years in
2015) [23].
HCV among PWID
In a 2015 report analysing the HCV situation among drug
users in Switzerland, it was estimated that 56% (27–58%)
of PWID are HCV antibody positive, although prevalence
rates vary by harm reduction segment as well as by age
[24, 25]. On the basis of a spontaneous clearance rate of
25% [26], the viraemic prevalence in the PWID population
was 42%, compared with a 1% viraemic prevalence in the
general adult population [1]. On average, new PWID were
assumed to become HCV infected within 2 years of initi-
ating injecting. As of 2011, approximately 20–30 currently
injecting PWID have received antiviral treatment annually
for HCV, all of whom were enrolled in OST or HAT (ex-
pert consensus).
PWID behaviour and harm reduction programmes
Since 1999, there have been an average of 17 693 partic-
ipants enrolled in OST (range 16 960 in 2013 to 18 393
in 2000) [8, 24]. In 2014, there were 17 008 OST par-
ticipants, among whom an estimated 27.4% (8.3–47.1%)
continued to inject illicit drugs while on treatment [8, 24,
27–29]. The percent of OST participants who continued to
inject on treatment was estimated from the ARUD centres
in Zurich (25.5–28.2% between 2010 and 2013) as well as
through OST registries in Zurich (13.5% with a range of
8.3–47.1% in 2013) and in Vaud (36%, or 601 of 1666 pa-
tients, between 2001 and 2008) [27–29]. Additionally, in
2013, 1598 individuals were enrolled in HAT [30, 31], of
whom 54–66% had been prescribed injectable (or combi-
nation oral/injectable) heroin [27, 30]. HAT participation
has increased nearly 10% over the past 10 years (1464
participants in 2003) (personal communication, Swiss Re-
search Institute for Public Health).
The average monthly distribution of sterile syringes has
been decreasing since the programme’s inception in 1993
[24]. In 2012, approximately 300 000 sterile syringes were
distributed per month [24]. Assuming an average use of
1.3 sterile syringes per PWID per day, approximately 7790
PWID were actively engaged with an NSP, based on the
estimation that the number of needles per PWID per month
is between 29.9 and 76.5 [23]. OST and HAT participants
were assumed to use an average of 29.9 sterile needles
per month, while PWID not involved in these programmes
were assumed to use an average of 53.2 sterile needles per
month (average of 29.9 and 76.5) (expert consensus). A
midpoint was chosen for the population of PWID not en-
gaged with harm reduction services, to account for PWID
who may inject with greater frequency, but not necessarily
with a sterile syringe on each occasion (expert consensus).
Scenarios
Scenarios were developed to assess the impact of provid-
ing HCV treatment with direct acting antivirals. Project-
ed sustained viral response rates in Switzerland have been
described previously [1]. Treatment of 1, 5, 10 or 15%
of the total HCV+ PWID population was modelled from
2016, and the resulting impact on total HCV infections and
secondary infections was calculated. In the absence of be-
havioural changes, cured PWID remained susceptible to
secondary infection with HCV, with an average time to in-
fection of 2 to 4 years among PWID outside of harm re-
duction [24].
Additionally, two sub-scenarios were considered under an
aggressive treatment paradigm to examine the impact of
(1) targeting treatment to OST/HAT programme partici-
pants only; (2) providing counselling to result in a 10, 30
or 50% reduction in risk behaviour following sustained vi-
ral response.
Sensitivity analysis
The uncertainty in inputs, as detailed in table 1, was cap-
tured as a range using Beta-PERT. Monte Carlo simu-
lations were run to determine 95% uncertainty intervals
(UIs) using Crystal Ball, an Excel add-in by Oracle.
Results
Baseline
In 2015, there were an estimated 10 160 PWID in Switzer-
land, more than 85% of whom were engaged in harm re-
duction efforts including NSPs and/or OST or HAT. Al-
though 18 610 individuals were enrolled in OST or HAT,
only 5620 continued to inject. NSP services were accessed
by 7790 PWID, and approximately 4780 PWID on an NSP
were also being treated with OST or HAT (fig. 1). Overall,
4200 PWID were HCV infected, with an estimated 55 new
viraemic HCV infections occurring in 2015 (12.9 per 1000
PWID).
The highest annual number of new viraemic infections oc-
curred in the segment of the PWID population that was not
involved in harm reduction (25, 95% UI 23–30, new cas-
es or an infection rate of 19 per 1000 PWID), followed by
20 (95% UI 18–24) cases occurring among PWID engaged
in both NSP and OST/HAT (infection rate of 4 per 1000
PWID) (fig. 2). Treating approximately 25 PWID engaged
in both NSPs and OST/HAT annually resulted in fewer
than five secondary infections annually. Over the next 15
years, the HCV infected PWID population was estimated
to decrease by 60% (95% UI 56–61%), probably owing to
an aging population and current harm reduction efforts.
Increased treatment
Treatment of 42 patients annually (1% of the HCV+ PWID
population) resulted in a 65% decrease in total HCV in-
fections among PWID by 2030 (fig. 3). Secondary infec-
tions among treated and cured HCV patients were project-
ed to peak in 2027 at 13 annually and remain constant until
2030. Under this scenario, a total of 660 patients would be
treated (including re-treatments) between 2015 and 2030,
with a total of 155 secondary infections observed (25.8
secondary infections per 100 treated patients) (fig. 4).
Treatment of 210 patients annually (5% of the HCV+
PWID population) resulted in a 95% reduction in total
HCV infections among PWID by 2030. Secondary infec-
tions were projected to peak in 2023 at 40, before decreas-
ing to 15 annually by 2030 (fig. 3). Under this scenario, a
total of 3055 patients would be treated (including re-treat-
ments) between 2015 and 2030, with a cumulative 440 sec-
ondary infections projected (14.4 secondary infections per
100 treated patients) (fig. 4).
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Aggressive initial treatment
Treatment of 425 patients annually (10% of the PWID pop-
ulation) resulted in a greater than 99% reduction in total
HCV infections among PWID by 2025. Secondary infec-
tions were projected to peak in 2024 at 55, before decreas-
ing to nearly zero annually by 2026 (fig. 3). Under this
scenario, treatment of 425 patients annually could be sus-
tained only until 2022, after which point the model ran out
of patients and treatment numbers were reduced to few-
er than five by 2027. From 2016 to 2030, a total of 3730
patients would be treated (including re-treatments) with a
cumulative 335 secondary infections projected (8.9 sec-
ondary infections per 100 treated patients) (fig. 4).
Treating 15% of the HCV+ PWID population annually
(635 patients annually or 3920 total) achieved >99% re-
duction one year earlier (2024) than the 10% scenario (fig.
3). Secondary infections peaked earlier (2019) and higher
(n = 60), and amounted to a lower cumulative number (n
= 260, or 6.6 secondary infections per 100 treated patients)
(fig. 4).
Sub-scenarios
Within the 10% treatment scenario, two sub-scenarios
were considered.
1. Targeting treatment to OST/HAT programme partici-
pants. In this scenario, the 425 patients treated annual-
ly were identified through their participation in OST/
HAT, and by 2030 a total of 3790 patients were treat-
ed. The overall HCV prevalence was reduced by 90%,
and secondary infections peaked in 2022 (n = 55) with
615 cumulative secondary infections (16.1 secondary
infections per 100 treated patients) (fig. 5) due to trans-
mission across harm reduction segments.
2. Counselling after a sustained viral response to achieve
a 10, 30 or 50% reduction in risk behaviour (among
patients on and off of harm reduction programmes). At
all levels of behaviour change, the total prevalence was
reduced by >99%. Compared with the original 10%
treatment scenario, counselling was successful in re-
ducing the number of cumulative secondary infections
(300, 225 and 155 cumulative secondary infections as-
sociated with a 10, 30 and 50% behaviour change, re-
spectively) (fig. 5).
Discussion
The aim of this analysis was to estimate the size and distri-
bution of the HCV infected PWID population in Switzer-
land and to assess the impact of treatment on the total num-
ber of HCV infections, as well as the number of secondary
infections following a HCV cure. Harm reduction mea-
sures including needle and syringe programmes and opiate
substitution therapy are estimated to cover 85% of PWID
in Switzerland, and the HCV RNA prevalence has been de-
creasing over time [24]. Assuming constant levels of treat-
ment and harm reduction, the HCV infected PWID popu-
lation is anticipated to decrease over the next 15 years. In-
creasing treatment across all segments of PWID (whether
engaged in harm reduction programmes or not) will reduce
the prevalence of HCV among PWID at every level of
treatment. In the absence of behavioural changes, an in-
crease in secondary infections should be anticipated as a
result of re-exposure to the HCV virus within an injecting
circle. This continued exposure to virus through high-risk
activities has been identified, historically, when an individ-
ual is found positive for more than one HCV genotype.
Although an increase in secondary infections is to be ex-
pected, it is only a temporary concern, assuming treatment
levels exceed 5% of HCV+ PWID.
PWID engaged in harm reduction programmes had a lower
infection rate (4 per 1000 PWID per year, compared with
19 per 1000 PWID per year) than those outside of harm re-
duction programmes. Treatment of OST/HAT participants
Table 1: Model input data.
Category Item Source Year Base-case Range
[25] 2000 18 415 15 900–31 800
[23] 2006 15 113 10 950–21 900
Active PWID
Dr. Gervasoni; consen-
sus
2014 10 160 8000–12 000
PWID population
Mortality rate [5] 1.38% 1.25–58%
Anti-HCV prevalence [24, 25] 2011 56% 27–58%
Spontaneous clearance rate [26] 25%
Treated Consensus estimate 2015 25 20–30
HCV among PWID
Probability of transmission
from a contaminated needle
[14–16] 1.80% 1.00–3.75%
1999–2013 17 693 16 960Participants enrolled [8]
2014 17 008
Participants injecting [8, 24, 27–29] 2014 27.4% 8.3–47.1%
Opiate substitution ther-
apy
Reduction in unsafe injections
while on OST
[17–22] 59.0% 54.0–66.0%
Participants enrolled [31] 2003 1464
[30, 31] 2013 1598
Heroin assisted therapy
Participants injecting [27, 30] 54–66%
Sterile syringes distributed per
month (yearly average)
[24] 2012 300 000
Needles used per PWID per
month
[23]; consensus estimate 2015 53.2 29.9–76.5
Needle and syringe pro-
grammes
Reduction in unsafe injections
while on NSP
[17–22] 59.0% 54.0–66.0%
HCV = hepatitis C virus; NSP = needle and syringe programme; OST = opiate substitution therapy; PWID = people who inject drugs
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alone, however, would not be sufficient to reduce the num-
ber of new infections at a national level. From a modelling
perspective, this is primarily due to the assumption that
some PWID on OST/HAT will inject with individuals who
are not engaged in harm reduction, providing a consistent
re-introduction of virus into the injecting networks of pa-
tients on harm reduction. Providing counselling opportuni-
ties to promote reductions in risk behaviour was found to
be effective at reducing the number of new infections, even
when a low success rate (10%) was assumed.
HCV transmission occurs primarily as a result of intra-
venous contact with HCV infected blood. In the absence
of high-risk behaviours, including the sharing of injection
paraphernalia, the risk of HCV transmission is assumed to
be negligible. Thus, a history of injection drug use, or even
current injection drug use, alone should not be considered
contraindications for HCV treatment. Only one quarter of
people with a history of injection drug use are estimated to
continue injecting, and only 10% of PWID are estimated to
share injecting materials. Furthermore, approximately 40%
of PWID are HCV-RNA infected. If this relatively small
subset of the population (active injection drug users who
share injecting materials and are HCV-RNA+) carries the
largest risk of acquiring or transmitting HCV, then the re-
mainder of HCV-RNA+ individuals (former injection drug
users or active injection drug users who do not share inject-
ing materials) would be recommended for treatment. Be-
cause of the complex and unique situation of active drug
users, the decision to treat HCV among PWID should be at
the discretion of the provider who best knows the individ-
ual. Furthermore, a comprehensive approach to treatment,
including counselling, linkage to harm reduction services
and treatment follow-up should be considered as the best
chance to prevent HCV re-exposure.
A few limitations exist within the analysis and the assump-
tions. Wherever possible, uncertainty in estimates has been
captured as a range to inform sensitivity analysis. It is dif-
ficult, however, to estimate the size of the hidden PWID
population (the population not in contact with harm reduc-
tion services) and predict future changes in this population
size. Although historical trends show that injection drug
use has been decreasing in Switzerland, future uptake of
injection drugs remains unknown. In the absence of bet-
ter information, the total number of PWID was assumed
to remain constant after 2015. This could overestimate the
number of new infections in the future, as well as the num-
ber of treatments needed to curb HCV in this population.
Additionally, changing behaviours among individuals are
often lost within aggregated analyses. In this instance, as-
sumptions such as needle sharing and injection frequency
Figure 1: Size of the OST/HAT, NSP and PWID populations, 2015.HAT = heroin assisted therapy; NSP = needle and syringe programme;
OST = opiate substitution therapy; PWID = people who inject drugs
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are captured as averages and take 1 year to fully imple-
ment. However, in real life the individuals contributing to
these averages may be at very different risks for HCV.
Preferentially directing treatment to PWID who are at
highest risk of transmitting HCV owing to sharing behav-
iours would allow for a more substantial reduction in new
infections; however, needle sharing is frequently underes-
timated as a result of concerns about stigma. Thus, it is
important that treatment decisions be made at the provider
level, on the basis of the individual, but with adequate sys-
tematic resources (including counselling, harm reduction
and follow-up care) to prevent re-infection.
Another limitation is that the risk of transmitting or ac-
quiring HCV was considered negligible among PWID who
had discontinued injecting, or who were injecting but not
sharing injecting equipment. This approach may have un-
derestimated the number of new cases occurring; however,
Figure 2: Distribution of new HCV infections among PWID, by segment, 2015-2030.HAT = heroin assisted therapy; HCV = hepatitis C virus;
NSP = needle and syringe programme; OST = opiate substitution therapy; PWID = people who inject drugs
Figure 3: (a) Total HCV cases; (b) viraemic new infections (primary and secondary infections); and (c) viraemic secondary infections, by per-
cent of the total HCV+ PWID population treated, 2015–2030.HCV = hepatitis C virus; PWID = people who inject drugs
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given the lower risk of transmission, it is unlikely that the
number of new cases would be substantially increased.
Finally, the ability to model increased treatment does not
reflect the availability of resources to provide the treat-
ment. Currently, HCV treatment is provided to PWID at
some (but not all) OST centres, as well as at hepatology or
infectious disease units based at the secondary and tertiary
care level. The present system is not equipped for a large
increase in patients, and novel approaches to treatment
should be considered. These approaches could include the
expansion of treatment to all OST providers and centres
and/or the provision of treatment in consumption rooms. It
will be important to evaluate the capacity of physicians and
harm reduction service providers before recommendations
can be made to scale up efforts.
Conclusion
A strategy to treat PWID should carefully consider the im-
pact of time and scale. Rapid aggressive scale-ups in treat-
ment, combined with harm reduction programmes, offer
the opportunity to avoid secondary infections in the mid-
term, as well as to lower the cumulative number of patients
treated. Of course, treatment among PWID who are inject-
ing safely, or among individuals who have discontinued
injecting, is always recommended. Cost of treatment with
direct acting antivirals and cost savings incurred through
prevention of secondary HCV related clinical complica-
tions avoided have not been taken into account.
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